What is ANI Pharmaceuticals, Inc.'s earnings per share (EPS)?

ANI Pharmaceuticals, Inc. (ANIP) reported diluted earnings per share of $3.32 for fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

ANI Pharmaceuticals (ANIP) Financials

ANIP NASDAQ

Trailing 12 months to June 30, 2026

Revenue $978.4M +30.9% YoY

Net Income $108.3M n/m YoY

EPS (Diluted) $4.63 n/m YoY

Free Cash Flow $173.0M +37.9% YoY

Market Cap $1.7B as of Oct 26, 2026

Price / Sales 1.7x on $978.4M revenue, trailing 12 months to June 30, 2026

Price / Earnings 15.4x on $108.3M net income, trailing 12 months to June 30, 2026

Price / Book 2.8x on $597.2M equity, Q2 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 26, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Aug 7, 2026 Currency USD FYE December

Newest figures come from the 10-Q for Q2 FY2026, filed Aug 7, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the ANIP SEC filings page.

ANI Pharmaceuticals, Inc. (ANIP) reported $978.4M in revenue over the twelve months to Jun 30, 2026, up 30.9% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI ANIP FY2025 2026-10-25

The business has become a cash-generating model, but expansion has increased liabilities faster than equity.

In FY2025, operating cash flow of $185M exceeded net income of $78M, showing that reported earnings converted into more cash than accounting profit alone suggests. Free cash flow reached $171M while capital expenditures were only $13.8M, so reinvestment consumed a relatively small portion of internally generated cash.

Revenue increased 43.8% in FY2025 while selling, general and administrative costs rose 27.3%, indicating that overhead absorbed growth more efficiently. Operating margin reached 12.6% after sitting near break-even in FY2024, marking a sharp improvement in operating economics rather than mere top-line expansion.

From FY2023 to FY2025, total liabilities grew 101.3% while equity grew only 25.0%, meaning the balance sheet expanded with greater dependence on obligations. Debt-to-equity was just 0.5x and the current ratio was 2.7x in FY2025, so the financing change is concentrated in the broader liability structure rather than long-term debt alone.

Financial Health Signals

Financial Health Score 69/100

Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group, and the overall is the average of the dimensions that can be computed. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of ANI Pharmaceuticals, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Profitability

ANI Pharmaceuticals, Inc. has an operating margin of 12.6%, meaning the company retains $13 of operating profit per $100 of revenue. This results in a moderate score of 43/100, indicating healthy but not exceptional operating efficiency. This is up from 0.1% the prior year.

Growth

ANI Pharmaceuticals, Inc.'s revenue surged 43.8% year-over-year to $883.4M, reflecting rapid business expansion. This strong growth earns a score of 91/100.

Leverage

ANI Pharmaceuticals, Inc. carries a low D/E ratio of 0.54, meaning only $0.54 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 86/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

With a current ratio of 2.71, ANI Pharmaceuticals, Inc. holds $2.71 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 74/100.

Cash Flow

ANI Pharmaceuticals, Inc. converts 19.4% of revenue into free cash flow ($171.4M). This strong cash generation earns a score of 80/100.

Returns

ANI Pharmaceuticals, Inc.'s ROE of 14.5% shows moderate profitability relative to equity, earning a score of 37/100. This is up from -4.6% the prior year.

Altman Z-Score Grey Zone

2.35

ANI Pharmaceuticals, Inc. scores 2.35, placing it in the grey zone between 1.81 and 2.99. The largest contribution to the score comes from a market capitalization of $1.7B against total liabilities of $899.7M. This signals moderate financial risk that warrants monitoring.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Strong

7/9

ANI Pharmaceuticals, Inc. passes 7 of 9 financial strength tests. All 4 profitability signals pass (positive income, cash flow, and earnings quality), 1 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.

Earnings Quality Cash-Backed

2.36x

For every $1 of reported earnings, ANI Pharmaceuticals, Inc. generates $2.36 in operating cash flow ($185.2M OCF vs $78.3M net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.

Interest Coverage Adequate

3.41x

ANI Pharmaceuticals, Inc. earns $3.41 in operating income for every $1 of interest expense ($111.1M vs $32.6M). This adequate coverage means the company can meet its interest obligations, but has limited cushion if earnings fall.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$266.0M

YoY+25.9%

QoQ+12.0%

5Y CAGR+40.5%

10Y CAGR+23.8%

ANI Pharmaceuticals, Inc. generated $266.0M in revenue in Q2 2026. This represents an increase of 25.9% from the same quarter a year earlier. Against the prior quarter it is up 12.0%.

EBITDA

$60.1M

YoY+61.7%

QoQ+0.5%

5Y CAGRn/m

10Y CAGR+18.3%

ANI Pharmaceuticals, Inc.'s EBITDA was $60.1M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 61.7% from the same quarter a year earlier. Against the prior quarter it is up 0.5%.

Net Income

$24.7M

YoY+189.1%

QoQ-16.2%

5Y CAGRn/m

ANI Pharmaceuticals, Inc. reported $24.7M in net income in Q2 2026. This represents an increase of 189.1% from the same quarter a year earlier. Against the prior quarter it is down 16.2%.

EPS (Diluted)

$1.05

YoY+191.7%

QoQ-18.0%

ANI Pharmaceuticals, Inc. earned $1.05 per diluted share (EPS) in Q2 2026. This represents an increase of 191.7% from the same quarter a year earlier. Against the prior quarter it is down 18.0%.

Cash & Balance Sheet

Free Cash Flow

$53.6M

YoY-25.3%

QoQ+2.5%

5Y CAGRn/m

10Y CAGR+35.2%

ANI Pharmaceuticals, Inc. generated $53.6M in free cash flow in Q2 2026, representing cash available after capex. This represents a decrease of 25.3% from the same quarter a year earlier. Against the prior quarter it is up 2.5%.

Cash & Debt

$360.2M

YoY+65.4%

QoQ+15.8%

5Y CAGR+71.5%

10Y CAGR+37.4%

ANI Pharmaceuticals, Inc. held $360.2M in cash against $280.2M in long-term debt as of Q2 2026.

Shares Outstanding

Diluted avg 22M

ANI Pharmaceuticals, Inc. had a weighted average of 22M diluted shares in Q2 2026; the shares outstanding count is not reported for that period.

Dividends Per Share

Not reported for Q2 2026.

Margins & Returns

Gross Margin

62.4%

YoY-2.3pp

QoQ+1.8pp

5Y change+8.2pp

ANI Pharmaceuticals, Inc.'s gross margin was 62.4% in Q2 2026, indicating the percentage of revenue retained after direct costs. This is down 2.3 percentage points from the same quarter a year earlier. Against the prior quarter it is up 1.8 percentage points.

Operating Margin

15.2%

YoY+8.6pp

QoQ-1.2pp

5Y change+47.2pp

10Y change-1.4pp

ANI Pharmaceuticals, Inc.'s operating margin was 15.2% in Q2 2026, reflecting core business profitability. This is up 8.6 percentage points from the same quarter a year earlier. Against the prior quarter it is down 1.2 percentage points.

Net Margin

9.3%

YoY+5.3pp

QoQ-3.1pp

5Y change+38.3pp

ANI Pharmaceuticals, Inc.'s net profit margin was 9.3% in Q2 2026, showing the share of revenue converted to profit. This is up 5.3 percentage points from the same quarter a year earlier. Against the prior quarter it is down 3.1 percentage points.

Return on Equity

4.1%

YoY+2.2pp

QoQ-1.1pp

5Y change+11.5pp

ANI Pharmaceuticals, Inc.'s quarterly ROE was 4.1% in Q2 2026: one quarter's net income over shareholder equity, not annualized. This is up 2.2 percentage points from the same quarter a year earlier. Against the prior quarter it is down 1.1 percentage points.

Capital Allocation

R&D Spending

$14.7M

YoY-10.8%

QoQ+39.1%

5Y CAGR+39.4%

ANI Pharmaceuticals, Inc. invested $14.7M in research and development in Q2 2026. This represents a decrease of 10.8% from the same quarter a year earlier. Against the prior quarter it is up 39.1%.

Share Buybacks

$813K

YoY+47.5%

QoQ-95.9%

5Y CAGR+11.7%

ANI Pharmaceuticals, Inc. spent $813K on share buybacks in Q2 2026, returning capital to shareholders by reducing shares outstanding. This represents an increase of 47.5% from the same quarter a year earlier. Against the prior quarter it is down 95.9%.

Capital Expenditures

$3.1M

YoY-23.9%

QoQ-49.7%

5Y CAGR+26.8%

10Y CAGR+15.6%

ANI Pharmaceuticals, Inc. invested $3.1M in capex in Q2 2026, funding long-term assets and infrastructure. This represents a decrease of 23.9% from the same quarter a year earlier. Against the prior quarter it is down 49.7%.

ANIP Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

ANIP quarterly income statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Revenue	$978.4M	$883.4M+43.8%	$614.4M+26.2%	$486.8M+53.9%	$316.4M+46.4%	$216.1M+3.7%	$208.5M+0.9%	$206.5M+2.5%	$201.6M+14.0%	$176.8M+37.5%	$128.6M+68.5%	$76.3M+36.4%	$56.0M+86.1%	$30.1M+47.7%	$20.4M+4581.3%	$435K
Cost of Revenue	$387.4M	$341.3M+36.4%	$250.2M+37.8%	$181.5M+30.8%	$138.8M+37.9%	$100.6M+15.4%	$87.2M+38.0%	$63.2M-13.5%	$73.0M-7.6%	$79.0M+62.0%	$48.8M+284.3%	$12.7M+10.6%	$11.5M+15.0%	$10.0M+8.8%	$9.2M	N/A
Gross Profit	$591.0M	$542.1M+48.8%	$364.2M+19.3%	$305.3M+71.9%	$177.6M+53.7%	$115.5M-4.8%	$121.3M-15.4%	$143.4M+11.5%	$128.6M+31.4%	$97.8M+22.5%	$79.8M+25.5%	$63.6M+43.0%	$44.5M+121.3%	$20.1M+79.5%	$11.2M	N/A
R&D Expenses	$49.9M	$51.7M+15.9%	$44.6M+30.0%	$34.3M+53.6%	$22.3M+96.3%	$11.4M-28.9%	$16.0M-19.2%	$19.8M+28.7%	$15.4M+69.7%	$9.1M+212.1%	$2.9M+1.1%	$2.9M+7.3%	$2.7M+56.4%	$1.7M+47.8%	$1.2M-97.4%	$44.2M
SG&A Expenses	$324.8M	$317.7M+27.3%	$249.6M+54.4%	$161.7M+30.4%	$124.0M+47.2%	$84.3M+29.7%	$65.0M+16.4%	$55.8M+26.7%	$44.1M+39.5%	$31.6M+13.5%	$27.8M+31.5%	$21.2M+18.0%	$17.9M+9.4%	$16.4M+72.1%	$9.5M+36.4%	$7.0M
Operating Income	$150.4M	$111.1M+18922.8%	$584K-98.8%	$47.0Mn/m	-$35.3Mn/m	-$39.8Mn/m	-$16.0M-198.0%	$16.4M-53.8%	$35.4M+24.8%	$28.3M+41.1%	$20.1M-38.6%	$32.7M+63.5%	$20.0M+2127.8%	$898Kn/m	-$42K	N/A
EBITDA	N/A	$202.5M+196.4%	$68.3M-36.0%	$106.8M+392.2%	$21.7M+190.8%	$7.5M-73.9%	$28.6M-53.1%	$61.0M-11.8%	$69.1M+22.8%	$56.3M+32.6%	$42.4M+7.1%	$39.6M+65.8%	$23.9M+1089.4%	$2.0M+282.5%	$525K	N/A
Interest Expense	$31.3M	$32.6M-3.2%	$33.6M-5.6%	$35.6M+25.0%	$28.5M+138.7%	$11.9M+26.0%	$9.5M-29.6%	$13.5M-9.7%	$14.9M+31.7%	$11.3M+0.3%	$11.3M+1.4%	$11.1M+1274.0%	$811K+73.7%	$467K-64.8%	$1.3M+94.7%	$682K
Income Tax	$34.3M	$17.5Mn/m	-$3.7M-437.6%	$1.1Mn/m	-$14.8Mn/m	-$13.5Mn/m	-$3.4Mn/m	-$2.9M-164.5%	$4.6M-73.8%	$17.4M+267.3%	$4.7M-25.4%	$6.4Mn/m	-$9.4M-46940.0%	$20Kn/m	-$36Kn/m	$0
Net Income	$108.3M	$78.3Mn/m	-$18.5M-198.6%	$18.8Mn/m	-$47.9Mn/m	-$42.6Mn/m	-$22.5M-470.0%	$6.1M-60.7%	$15.5Mn/m	-$1.1M-127.4%	$3.9M-74.4%	$15.4M-46.5%	$28.7M+9450.5%	$301Kn/m	-$1.5Mn/m	-$51.6M
EPS (Basic)	N/A	$3.50n/m	-$1.04-220.9%	$0.86n/m	-$3.05n/m	-$3.40n/m	-$1.88-468.6%	$0.51-61.1%	$1.31n/m	-$0.09-126.5%	$0.34-74.6%	$1.34-48.7%	$2.61	-$0.92	-$1.27	-$3.15
EPS (Diluted)	$4.63	$3.32n/m	-$1.04-222.4%	$0.85n/m	-$3.05n/m	-$3.40n/m	-$1.88-476.0%	$0.50-61.5%	$1.30n/m	-$0.09-126.5%	$0.34-74.2%	$1.32-49.0%	$2.59	-$0.92	-$1.27	-$3.15
Diluted Shares (Avg)	N/A	21M+9.9%	19M+6.2%	18M+11.9%	16M+29.1%	13M+5.3%	12M-0.6%	12M+2.3%	12M+1.9%	12M-0.2%	12M+0.1%	12M+4.6%	11M	5,071	22M	16M

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-K	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Revenue	$266.0M+25.9%	$237.5M+20.5%	$247.1M+29.6%	$227.8M+53.6%	$211.4M+53.1%	$197.1M+43.4%	$190.6M+44.8%	$148.3M+12.5%
Cost of Revenue	$100.2M+34.2%	$93.6M+28.1%	$100.3M+24.9%	$93.4M+48.1%	$74.6M+29.3%	$73.0M+48.6%	$80.3M+50.3%	$63.1M+31.1%
Gross Profit	$165.9M+21.3%	$143.9M+16.0%	$146.8M+33.1%	$134.4M+57.7%	$136.8M+70.2%	$124.1M+40.6%	$110.3M+41.0%	$85.3M+1.8%
R&D Expenses	$14.7M-10.8%	$10.6M+0.3%	$12.3M-26.3%	$12.3M+21.5%	$16.5M+126.6%	$10.6M+0.5%	$16.6M+68.7%	$10.1M-8.9%
SG&A Expenses	$91.7M+12.1%	$73.7M-3.8%	$82.8M+18.7%	$76.7M-3.1%	$81.8M+54.8%	$76.5M+59.4%	$69.7M+56.8%	$79.1M+88.2%
Operating Income	$40.5M+191.2%	$38.9M+48.5%	$34.8Mn/m	$36.2Mn/m	$13.9M+168.8%	$26.2M+29.0%	-$4.4M-165.1%	-$20.5M-214.3%
EBITDA	$60.1M+61.7%	$59.8M+21.8%	$57.4M+214.9%	$58.9Mn/m	$37.2M+87.1%	$49.1M+40.3%	$18.2M-16.9%	-$4.8M-114.4%
Interest Expense	$7.5M-8.8%	$7.6M-6.8%	$8.0M-9.6%	$8.3M+24.3%	$8.2M-9.3%	$8.1M-10.9%	$8.8M-23.3%	$6.7M-19.9%
Income Tax	$12.4M+526.8%	$10.7M+149.2%	$4.0Mn/m	$7.2Mn/m	$2.0Mn/m	$4.3M-39.6%	-$3.5Mn/m	-$7.3M-566.7%
Net Income	$24.7M+189.1%	$29.5M+88.1%	$27.5Mn/m	$26.6Mn/m	$8.5Mn/m	$15.7M-13.9%	-$10.3M-989.7%	-$24.2M-343.1%
EPS (Basic)	$1.09+194.6%	$1.31+87.1%	$1.24n/m	$1.19n/m	$0.37n/m	$0.70-16.7%	-$0.55	-$1.27-376.1%
EPS (Diluted)	$1.05+191.7%	$1.28+85.5%	$1.17n/m	$1.13n/m	$0.36n/m	$0.69-15.9%	-$0.55	-$1.27-382.2%
Diluted Shares (Avg)	22M+7.9%	22M+7.5%	N/A	21M+8.7%	20M+5.1%	20M+3.2%	N/A	19M+1.5%

ANIP Balance Sheet

ANIP quarterly balance sheet

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Total Assets	$1.4B+12.1%	$1.3B+42.0%	$904.4M+19.0%	$760.1M-1.5%	$771.6M+67.3%	$461.2M+1.0%	$456.8M+6.1%	$430.6M+4.5%	$412.1M+27.7%	$322.9M+13.2%	$285.3M+9.9%	$259.6M+483.3%	$44.5M+223.7%	$13.7M-78.0%	$62.4M
Current Assets	$753.1M+42.5%	$528.5M+1.7%	$519.8M+51.0%	$344.3M+7.0%	$321.8M+88.9%	$170.3M-9.3%	$187.7M+22.8%	$152.9M+16.2%	$131.6M+27.8%	$103.0M-46.5%	$192.6M-1.2%	$195.0M+603.5%	$27.7M+223.6%	$8.6M-85.2%	$58.0M
Cash & Equivalents	$285.6M+97.1%	$144.9M-34.5%	$221.1M+358.5%	$48.2M-51.9%	$100.3M+1175.4%	$7.9M-87.4%	$62.3M+44.9%	$43.0M+38.1%	$31.1M+13.8%	$27.4M-82.3%	$154.7M-8.5%	$169.0M+1422.2%	$11.1M+100854.5%	$11Kn/m	$0
Short-Term Investments	N/A	N/A	N/A	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0
Inventory	$143.1M+4.6%	$136.8M+23.0%	$111.2M+5.5%	$105.4M+29.0%	$81.7M+34.4%	$60.8M+26.2%	$48.2M+18.9%	$40.5M+7.4%	$37.7M+44.1%	$26.2M+95.6%	$13.4M+78.1%	$7.5M+113.7%	$3.5M+25.2%	$2.8M	N/A
Accounts Receivable	$281.1M+26.8%	$221.7M+36.8%	$162.1M-2.0%	$165.4M+28.7%	$128.5M+34.2%	$95.8M+32.8%	$72.1M+11.2%	$64.8M+10.3%	$58.8M+28.1%	$45.9M+109.3%	$21.9M+26.8%	$17.3M+38.2%	$12.5M+130.4%	$5.4M	N/A
Long-Term Investments	N/A	N/A	N/A	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0-100.0%	$3.4M+0.2%	$3.4M
Goodwill	$62.5M+4.2%	$60.0M+112.6%	$28.2M0.0%	$28.2M+1.2%	$27.9M+679.0%	$3.6M0.0%	$3.6M0.0%	$3.6M+94.8%	$1.8M0.0%	$1.8M0.0%	$1.8M0.0%	$1.8M0.0%	$1.8Mn/m	$0	N/A
Total Liabilities	$899.7M+5.1%	$855.9M+91.6%	$446.8M+6.0%	$421.5M+2.1%	$412.9M+55.5%	$265.5M+8.8%	$244.0M+4.6%	$233.3M-1.7%	$237.4M+54.9%	$153.2M+22.4%	$125.2M+4.5%	$119.8M+3285.3%	$3.5M-93.7%	$56.5M-41.6%	$96.7M
Current Liabilities	$278.1M+43.0%	$194.5M+33.7%	$145.5M+46.3%	$99.4M+13.6%	$87.5M+11.4%	$78.6M+27.4%	$61.7M-62.7%	$165.5M+322.0%	$39.2M+22.8%	$31.9M+171.8%	$11.8M-11.2%	$13.2M+274.0%	$3.5M-54.1%	$7.7M+6.7%	$7.2M
Non-Current Liabilities	$621.5M-6.0%	$661.5M+119.5%	$301.3M-6.4%	$322.1M-1.0%	$325.3M+74.0%	$186.9M+2.5%	$182.3M+168.9%	$67.8M-65.8%	$198.2M+63.4%	$121.3M+6.9%	$113.4M+6.5%	$106.5Mn/m	$0-100.0%	$48.8M-45.5%	$89.4M
Long-Term Debt	$291.8M-5.6%	$309.1M+8.5%	$284.8M-0.3%	$285.7M-0.3%	$286.5M+66.2%	$172.4M-1.9%	$175.8M+161.2%	$67.3M-3.8%	$69.9M	N/A	$113.4M+6.5%	$106.5Mn/m	$0	N/A	$17.3M
Total Equity	$540.7M+33.9%	$403.7M-6.7%	$432.7M+38.0%	$313.7M-6.0%	$333.9M+70.6%	$195.7M-8.0%	$212.8M+7.9%	$197.3M+12.9%	$174.8M+3.0%	$169.6M+6.0%	$160.1M+14.5%	$139.8M+241.3%	$41.0Mn/m	-$42.7Mn/m	-$34.3M
Retained Earnings	-$23.1Mn/m	-$100.3Mn/m	-$80.1Mn/m	-$97.3Mn/m	-$47.8Mn/m	-$5.0M-128.3%	$17.6M+53.1%	$11.5Mn/m	-$4.0Mn/m	-$2.9Mn/m	-$4.3Mn/m	-$19.7Mn/m	-$48.5Mn/m	-$43.8Mn/m	-$217.2M

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-K	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Total Assets	$1.5B+11.3%	$1.4B+10.0%	$1.4B+12.1%	$1.4B+9.4%	$1.3B+45.9%	$1.3B+41.3%	$1.3B+42.0%	$1.3B+44.7%
Current Assets	$825.4M+37.0%	$747.1M+39.3%	$753.1M+42.5%	$698.4M+34.0%	$602.6M+8.5%	$536.3M-0.8%	$528.5M+1.7%	$521.3M+4.8%
Cash & Equivalents	$360.2M+65.4%	$311.2M+107.7%	$285.6M+97.1%	$262.6M+81.1%	$217.8M-9.3%	$149.8M-34.5%	$144.9M-34.5%	$145.0M-24.9%
Inventory	$143.1M+3.5%	$143.5M+4.4%	$143.1M+4.6%	$146.5M-1.1%	$138.3M+10.3%	$137.4M+20.7%	$136.8M+23.0%	$148.0M+38.9%
Accounts Receivable	$274.5M+21.6%	$255.4M+15.9%	$281.1M+26.8%	$252.6M+28.6%	$225.7M+35.9%	$220.3M+27.8%	$221.7M+36.8%	$196.4M+9.8%
Goodwill	$62.5M+3.2%	$62.5M+3.0%	$62.5M+4.2%	$62.5M+3.4%	$60.5M+114.5%	$60.7M+115.0%	$60.0M+112.6%	$60.4M+114.1%
Total Liabilities	$896.9M+1.8%	$859.7M+1.3%	$899.7M+5.1%	$902.3M+5.3%	$881.4M+100.3%	$849.0M+94.0%	$855.9M+91.6%	$856.6M+96.8%
Current Liabilities	$283.7M+19.8%	$239.5M+18.7%	$278.1M+43.0%	$270.6M+42.4%	$236.8M+69.2%	$201.8M+47.4%	$194.5M+33.7%	$189.9M+41.4%
Non-Current Liabilities	$613.2M-4.9%	$620.2M-4.2%	$621.5M-6.0%	$631.8M-5.2%	$644.6M+114.7%	$647.1M+115.1%	$661.5M+119.5%	$666.6M+121.6%
Long-Term Debt	$280.2M-7.1%	$286.0M-6.3%	$291.8M-5.6%	$297.7M-4.9%	$301.5M+6.0%	$305.3M+7.3%	$309.1M+8.5%	$312.9M+9.8%
Total Equity	$597.2M+36.7%	$562.3M+34.3%	$540.7M+33.9%	$505.8M+24.6%	$436.8M-4.2%	$418.6M-7.4%	$403.7M-6.7%	$405.9M-5.6%
Retained Earnings	$31.1Mn/m	$6.4Mn/m	-$23.1Mn/m	-$50.6Mn/m	-$76.9Mn/m	-$85.0Mn/m	-$100.3Mn/m	-$89.6Mn/m

Not reported in any period shown, so not listed: Short-Term Investments, Long-Term Investments.

ANIP Cash Flow Statement

ANIP quarterly cash flow statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Operating Cash Flow	$189.5M	$185.2M+189.3%	$64.0M-46.2%	$119.0Mn/m	-$31.2M-1039.3%	$3.3M-78.2%	$15.3M-66.5%	$45.6M-32.0%	$67.1M+70.2%	$39.4M+43.5%	$27.5M+59.1%	$17.3M-21.6%	$22.0Mn/m	-$5.5Mn/m	-$137Kn/m	-$47.9M
Depreciation & Amortization	N/A	$91.4M+35.0%	$67.7M+13.3%	$59.8M+4.9%	$57.0M+20.6%	$47.3M+5.9%	$44.6M+0.1%	$44.6M+32.2%	$33.7M+20.8%	$27.9M+25.0%	$22.3M+223.8%	$6.9M+77.9%	$3.9M+249.4%	$1.1M+95.8%	$567K+282.5%	$148K
Stock-Based Compensation	N/A	$37.9M+29.3%	$29.3M+42.1%	$20.7M+41.5%	$14.6M+39.2%	$10.5M-18.9%	$12.9M+40.3%	$9.2M+35.9%	$6.8M+11.4%	$6.1M+0.4%	$6.1M+57.3%	$3.9M+12.6%	$3.4M+9408.3%	$36Kn/m	$0-100.0%	$1.2M
Capital Expenditures	$16.5M	$13.8M-14.8%	$16.2M+83.1%	$8.9M-0.1%	$8.9M+247.1%	$2.6M-58.3%	$6.1M-7.5%	$6.6M+15.5%	$5.7M-44.6%	$10.4M+127.1%	$4.6M+109.2%	$2.2M+94.9%	$1.1M+486.4%	$191K-34.6%	$292K-59.4%	$720K
Free Cash Flow	$173.0M	$171.4M+258.7%	$47.8M-56.6%	$110.1Mn/m	-$40.1M-5339.1%	$765K-91.6%	$9.1M-76.6%	$39.0M-36.4%	$61.3M+111.1%	$29.1M+26.8%	$22.9M+51.9%	$15.1M-27.9%	$20.9Mn/m	-$5.7Mn/m	-$429Kn/m	-$48.6M
Investing Cash Flow	-$21.9M	-$34.3Mn/m	-$404.7Mn/m	-$18.5Mn/m	-$15.7Mn/m	-$105.5Mn/m	-$68.3Mn/m	-$27.5Mn/m	-$27.4Mn/m	-$108.0Mn/m	-$149.1Mn/m	-$32.7Mn/m	-$35.8M	N/A	N/A	N/A
Financing Cash Flow	-$24.6M	-$9.9M-103.8%	$264.9M+292.9%	$67.4Mn/m	-$5.1M-102.6%	$194.6Mn/m	-$1.4M-215.1%	$1.3Mn/m	-$27.8M-138.4%	$72.4Mn/m	-$729K-168.4%	$1.1M-99.4%	$171.7Mn/m	-$3.7M-938.4%	$440K	N/A
Dividends Paid	$344K	$1.2M-28.8%	$1.6M0.0%	$1.6M0.0%	$1.6M+755.3%	$190Kn/m	$0n/m	$0	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	$22.2M	$12.2M+11.4%	$11.0M+119.8%	$5.0M+154.6%	$2.0M+120.1%	$890K-41.6%	$1.5M+47.7%	$1.0Mn/m	$0n/m	$0-100.0%	$2.5Mn/m	$0n/m	$0-100.0%	$433Kn/m	$0	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-K	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Operating Cash Flow	$56.7M-25.3%	$58.4M+66.8%	$30.4M+91.5%	$44.1M+253.2%	$75.8M+335.4%	$35.0M+91.5%	$15.9M-64.6%	$12.5M-61.2%
Depreciation & Amortization	$19.6M-15.6%	$20.9M-8.6%	$22.6M+0.1%	$22.6M+43.7%	$23.3M+58.4%	$22.9M+55.9%	$22.6M+48.7%	$15.7M+3.6%
Stock-Based Compensation	N/A	$10.2M+14.9%	N/A	N/A	N/A	$8.9M+27.9%	N/A	N/A
Capital Expenditures	$3.1M-23.9%	$6.1M+145.5%	$1.2M-48.0%	$6.1M+26.8%	$4.0M-9.8%	$2.5M-46.0%	$2.4M+5.0%	$4.8M+176.7%
Free Cash Flow	$53.6M-25.3%	$52.3M+60.8%	$29.1M+116.3%	$38.0M+395.3%	$71.8M+453.8%	$32.5M+137.6%	$13.5M-68.3%	$7.7M-74.8%
Investing Cash Flow	-$3.1Mn/m	-$11.3Mn/m	-$1.4Mn/m	-$6.2Mn/m	-$6.9Mn/m	-$19.8M-322.2%	-$10.7Mn/m	-$398.5Mn/m
Financing Cash Flow	-$4.6Mn/m	-$21.6Mn/m	-$4.6Mn/m	$6.3M-97.8%	-$1.7Mn/m	-$9.9Mn/m	-$4.9Mn/m	$291.0M+7650.5%
Dividends Paid	$0-100.0%	$0-100.0%	$0-100.0%	$344K-15.3%	$407K0.0%	$406K0.0%	$406K0.0%	$406K0.0%
Share Buybacks	$813K+47.5%	$19.8M+97.5%	$611K+92.1%	$1.0M+53.5%	$551K-57.6%	$10.0M+15.5%	$318K+37.7%	$680K+1.5%

ANIP Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

ANIP quarterly financial ratios

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Gross Margin	61.4%+2.1pp	59.3%-3.4pp	62.7%+6.6pp	56.1%+2.7pp	53.4%-4.7pp	58.2%-11.2pp	69.4%+5.6pp	63.8%+8.5pp	55.3%-6.8pp	62.1%-21.3pp	83.4%+3.9pp	79.5%+12.7pp	66.8%+11.8pp	55.0%	N/A
Operating Margin	12.6%+12.5pp	0.1%-9.6pp	9.7%+20.8pp	-11.2%+7.3pp	-18.4%-10.7pp	-7.7%-15.6pp	7.9%-9.6pp	17.5%+1.5pp	16.0%+0.4pp	15.6%-27.2pp	42.8%+7.1pp	35.7%+32.8pp	3.0%+3.2pp	-0.2%	N/A
Net Margin	8.9%+11.9pp	-3.0%-6.9pp	3.9%+19.0pp	-15.1%+4.6pp	-19.7%-8.9pp	-10.8%-13.8pp	2.9%-4.7pp	7.7%+8.3pp	-0.6%-3.7pp	3.1%-17.1pp	20.1%-31.2pp	51.4%+50.4pp	1.0%+8.4pp	-7.4%	-11859.7%
Return on Equity	14.5%+19.1pp	-4.6%-8.9pp	4.3%+19.6pp	-15.3%-2.5pp	-12.8%-1.2pp	-11.5%-14.4pp	2.9%-5.0pp	7.8%+8.5pp	-0.6%-2.9pp	2.3%-7.3pp	9.6%-11.0pp	20.6%+19.8pp	0.7%	N/A	N/A
Return on Assets	5.4%+6.9pp	-1.4%-3.5pp	2.1%+8.4pp	-6.3%-0.8pp	-5.5%-0.6pp	-4.9%-6.2pp	1.3%-2.3pp	3.6%+3.9pp	-0.3%-1.5pp	1.2%-4.2pp	5.4%-5.7pp	11.1%+10.4pp	0.7%+11.6pp	-10.9%+71.8pp	-82.7%
Current Ratio	2.710.0x	2.72-0.9x	3.57+0.1x	3.46-0.2x	3.68+1.5x	2.17-0.9x	3.04+2.1x	0.92-2.4x	3.35+0.1x	3.22-13.2x	16.38+1.6x	14.74+6.9x	7.83+6.7x	1.11-6.9x	8.03
Debt-to-Equity	0.54-0.2x	0.77+0.1x	0.66-0.3x	0.91+0.1x	0.860.0x	0.88+0.1x	0.83+0.5x	0.34-0.1x	0.40	N/A	0.71-0.1x	0.76+0.8x	0.00	N/A	N/A
Liabilities-to-Equity	1.66-0.5x	2.12+1.1x	1.03-0.3x	1.34+0.1x	1.24-0.1x	1.36+0.2x	1.150.0x	1.18-0.2x	1.36+0.5x	0.90+0.1x	0.78-0.1x	0.86+0.8x	0.09	N/A	N/A
Asset Turnover	0.61+0.1x	0.48-0.1x	0.54+0.1x	0.42+0.1x	0.28-0.2x	0.450.0x	0.450.0x	0.470.0x	0.430.0x	0.40+0.1x	0.27+0.1x	0.22-0.5x	0.68-0.8x	1.48+1.5x	0.01
FCF Margin	19.4%+11.6pp	7.8%-14.8pp	22.6%+35.3pp	-12.7%-13.0pp	0.4%-4.0pp	4.4%-14.5pp	18.9%-11.6pp	30.4%+14.0pp	16.4%-1.4pp	17.8%-1.9pp	19.8%-17.6pp	37.4%+56.2pp	-18.9%-16.8pp	-2.1%	-11166.0%

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-K	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Gross Margin	62.4%-2.3pp	60.6%-2.4pp	59.4%+1.5pp	59.0%+1.5pp	64.7%+6.5pp	62.9%-1.3pp	57.9%-1.5pp	57.5%-6.0pp
Operating Margin	15.2%+8.6pp	16.4%+3.1pp	14.1%+16.4pp	15.9%+29.7pp	6.6%+2.8pp	13.3%-1.5pp	-2.3%-7.4pp	-13.8%-27.4pp
Net Margin	9.3%+5.3pp	12.4%+4.5pp	11.1%+16.5pp	11.7%+28.0pp	4.0%+5.7pp	8.0%-5.3pp	-5.4%-6.3pp	-16.3%-23.8pp
Return on Equity	4.1%+2.2pp	5.2%+1.5pp	5.1%+7.6pp	5.3%+11.2pp	2.0%+2.5pp	3.8%-0.3pp	-2.5%-2.8pp	-5.9%-8.3pp
Return on Assets	1.7%+1.0pp	2.1%+0.9pp	1.9%+2.7pp	1.9%+3.8pp	0.6%+0.9pp	1.2%-0.8pp	-0.8%-0.9pp	-1.9%-3.0pp
Current Ratio	2.91+0.4x	3.12+0.5x	2.710.0x	2.58-0.2x	2.54-1.4x	2.66-1.3x	2.72-0.9x	2.74-1.0x
Debt-to-Equity	0.47-0.2x	0.51-0.2x	0.54-0.2x	0.59-0.2x	0.69+0.1x	0.73+0.1x	0.77+0.1x	0.77+0.1x
Liabilities-to-Equity	1.50-0.5x	1.53-0.5x	1.66-0.5x	1.78-0.3x	2.02+1.1x	2.03+1.1x	2.12+1.1x	2.11+1.1x
Asset Turnover	0.180.0x	0.170.0x	0.170.0x	0.160.0x	0.160.0x	0.150.0x	0.150.0x	0.120.0x
FCF Margin	20.2%-13.8pp	22.0%+5.5pp	11.8%+4.7pp	16.7%+11.5pp	34.0%+24.6pp	16.5%+6.5pp	7.1%-25.2pp	5.2%-17.9pp

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
ANI Pharmaceuticals, Inc. ANIP	FY2025	$883.4M	$78.3M	8.9%	$1.7B	69/100
Alvotech ALVO	FY2025	$586.3M	$27.9M	4.8%	$1.6B	33/100
Indivior Pharmaceuticals, Inc. INDV	FY2025	$1.2B	$210.0M	17.0%	$4.1B	43/100
Supernus Pharmaceuticals, Inc. SUPN	FY2025	$719.0M	-$38.5M	-5.4%	$2.4B	52/100
Amneal Pharmaceuticals, Inc. AMRX	FY2025	$3.0B	$72.1M	2.4%	$7.3B	56/100
HUTCHMED (China) Limited HCM	FY2025	$548.5M	$456.9M	83.3%	$2.5B	42/100

Where ANI Pharmaceuticals, Inc. Ranks

Frequently Asked Questions

What is ANI Pharmaceuticals, Inc.'s annual revenue?

ANI Pharmaceuticals, Inc. (ANIP) reported $883.4M in total revenue for fiscal year 2025. This represents a 43.8% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is ANI Pharmaceuticals, Inc.'s revenue growing?

ANI Pharmaceuticals, Inc. (ANIP) revenue grew by 43.8% year-over-year, from $614.4M to $883.4M in fiscal year 2025.

Is ANI Pharmaceuticals, Inc. profitable?

Yes, ANI Pharmaceuticals, Inc. (ANIP) reported a net income of $108.3M over the trailing 12 months to June 30, 2026. In fiscal year 2025 it reported a net income of $78.3M, with a net profit margin of 8.9%.

What is ANI Pharmaceuticals, Inc.'s EBITDA?

ANI Pharmaceuticals, Inc. (ANIP) had EBITDA of $202.5M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does ANI Pharmaceuticals, Inc. have?

As of fiscal year 2025, ANI Pharmaceuticals, Inc. (ANIP) had $285.6M in cash and equivalents against $291.8M in long-term debt.

What is ANI Pharmaceuticals, Inc.'s gross margin?

ANI Pharmaceuticals, Inc. (ANIP) had a gross margin of 61.4% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is ANI Pharmaceuticals, Inc.'s operating margin?

ANI Pharmaceuticals, Inc. (ANIP) had an operating margin of 12.6% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is ANI Pharmaceuticals, Inc.'s net profit margin?

ANI Pharmaceuticals, Inc. (ANIP) had a net profit margin of 8.9% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is ANI Pharmaceuticals, Inc.'s return on equity (ROE)?

ANI Pharmaceuticals, Inc. (ANIP) has a return on equity of 14.5% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is ANI Pharmaceuticals, Inc.'s free cash flow?

ANI Pharmaceuticals, Inc. (ANIP) generated $171.4M in free cash flow during fiscal year 2025. This represents a 258.7% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is ANI Pharmaceuticals, Inc.'s operating cash flow?

ANI Pharmaceuticals, Inc. (ANIP) generated $185.2M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are ANI Pharmaceuticals, Inc.'s total assets?

ANI Pharmaceuticals, Inc. (ANIP) had $1.4B in total assets as of fiscal year 2025, including both current and long-term assets.

What are ANI Pharmaceuticals, Inc.'s capital expenditures?

ANI Pharmaceuticals, Inc. (ANIP) invested $13.8M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does ANI Pharmaceuticals, Inc. spend on research and development?

ANI Pharmaceuticals, Inc. (ANIP) invested $51.7M in research and development during fiscal year 2025.

Does ANI Pharmaceuticals, Inc. buy back shares?

Yes, ANI Pharmaceuticals, Inc. (ANIP) spent $12.2M on share buybacks during fiscal year 2025, returning capital to shareholders by reducing shares outstanding.

How many shares does ANI Pharmaceuticals, Inc. have outstanding?

ANI Pharmaceuticals, Inc. (ANIP) had 22M shares outstanding as of fiscal year 2025.

What is ANI Pharmaceuticals, Inc.'s current ratio?

ANI Pharmaceuticals, Inc. (ANIP) had a current ratio of 2.71 as of fiscal year 2025, which is generally considered healthy.

What is ANI Pharmaceuticals, Inc.'s debt-to-equity ratio?

ANI Pharmaceuticals, Inc. (ANIP) had a debt-to-equity ratio of 0.54 as of fiscal year 2025. We compute it as long-term debt divided by total shareholder equity, where long-term debt is the noncurrent part of the company's borrowings, so debt due within the next twelve months is not counted.

What is ANI Pharmaceuticals, Inc.'s liabilities-to-equity ratio?

ANI Pharmaceuticals, Inc. (ANIP) had a liabilities-to-equity ratio of 1.66 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity.

What is ANI Pharmaceuticals, Inc.'s return on assets (ROA)?

ANI Pharmaceuticals, Inc. (ANIP) had a return on assets of 5.4% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is ANI Pharmaceuticals, Inc.'s P/E ratio?

ANI Pharmaceuticals, Inc. (ANIP) trades at 15.4x earnings, its market capitalization divided by $108.3M net income, trailing 12 months to June 30, 2026. The market capitalization is $1.7B as of Oct 26, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is ANI Pharmaceuticals, Inc.'s price-to-sales ratio?

ANI Pharmaceuticals, Inc. (ANIP) trades at 1.7x sales, its market capitalization divided by $978.4M revenue, trailing 12 months to June 30, 2026. The market capitalization is $1.7B as of Oct 26, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is ANI Pharmaceuticals, Inc.'s Altman Z-Score?

ANI Pharmaceuticals, Inc. (ANIP) has an Altman Z-Score of 2.35, placing it in the Grey Zone (moderate risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is ANI Pharmaceuticals, Inc.'s Piotroski F-Score?

ANI Pharmaceuticals, Inc. (ANIP) has a Piotroski F-Score of 7 out of 9, indicating strong financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are ANI Pharmaceuticals, Inc.'s earnings high quality?

ANI Pharmaceuticals, Inc. (ANIP) has an earnings quality ratio of 2.36x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can ANI Pharmaceuticals, Inc. cover its interest payments?

ANI Pharmaceuticals, Inc. (ANIP) has an interest coverage ratio of 3.41x, meaning it can adequately cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is ANI Pharmaceuticals, Inc.?

ANI Pharmaceuticals, Inc. (ANIP) scores 69 out of 100 on our Financial Health Score, indicating strong standing within its operating companies peer group. The score is the average of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.